Phenytoin alters the disposition of topotecan and N-desmethyl topotecan in a patient with medulloblastoma

Clinical Cancer Research

Volumn 4, Issue 3, 1998, Pages 783-789

  Zamboni, William C ^a   Gajjar, Amar J ^a   Heideman, Richard L ^a   Beijnen, Jos H ^b   Rosing, Hilde ^b   Houghton, Peter J ^a,c   Stewart, Clinton F ^a,c  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b SLOTERVAART HOSPITAL   (Netherlands)

^c UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG METABOLITE; PHENYTOIN; TOPOTECAN;

ARTICLE; CASE REPORT; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CEREBROSPINAL FLUID LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG ELIMINATION; DRUG INFUSION; DRUG MIXTURE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HIGH RISK PATIENT; HUMAN; LIVER METABOLISM; MALE; MEDULLOBLASTOMA; METASTASIS; ORAL DRUG ADMINISTRATION; PRESCHOOL CHILD; PRIORITY JOURNAL; SEIZURE;

EID: 0031924558     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Pommier, Y. DNA topoisomerase I and II in cancer chemotherapy: update and perspectives. Cancer Chemother. Pharmacol., 32: 103-108, 1993.
2. Pommier, Y., Leteurtre, F., Fesen, M. R., Fujimori, A., Bertrand, R., Solary, E., Kohlhagen, G., and Kohn, K. W. Cellular determinants of sensitivity and resistance to DNA topoisomerase inhibitors. Cancer Invest., 12: 530-542, 1994.
3. Potmesil, M. Camptothecins. From bench research to hospital wards. Cancer Res., 54: 1431-1439, 1994.
4. Tanizawa, A., Fujimori, A., Fujimori, Y., and Pommier, Y. Comparison of topoisomerase I inhibition, DNA damage, and cytotoxicity of camptothecin derivatives presently in clinical trials. J. Natl. Cancer Inst., 86: 836-842, 1994.
5. Furman, W. L., Baker, S. D., Pratt, C. B., Rivera, G., Evans, W. E., and Stewart, C. F. Escalating systemic exposure to topotecan following a 120-hr continuous infusion in children with relapsed acute leukemia. J. Clin. Oncol., 14: 1504-1511, 1996.
6. Stewart, C. F., Baker, S. D., Heideman, R. L., Jones, D., Crom, W. R., and Pratt, C. B. Clinical pharmacodynamics of continuous infusion topotecan in children: systemic exposure predicts hematologic toxicity. J. Clin. Oncol., 12: 1946-1954, 1994.
7. Stewart, C. F., Zamboni, W. C., Crom, W. R., Gajjar, A. J., Heideman, R. L., Furman, W. L., Meyer, W. H., Houghton, P. J., and Pratt, C. B. Topoisomerase I interactive drugs in children with cancer. Invest. New Drugs, 14: 37-47, 1996.
8. Zamboni, W. C., Crom, W. R., Bowman, L. C., Pratt, C. B., Houghton, P. J., and Stewart, C. F. Interpatient variability in oral (PO) absorption of topotecan (TPT) in children with relapsed solid tumors. Clin. Pharmacol. Ther., 59: 198, 1996.
9. Zamboni, W. C., Santana, V. M., Gajjar, A. J., Meyer, W. H., Pappo, A. S., Houghton, P. J., and Stewart, C. F. Pharmacokinetically guided dose adjustment reduces variability in topotecan (TPT) systemic exposure in children with solid tumors. Proc. Am. Soc. Clin. Oncol., 16: 205, 1997.
10. Zamboni, W. C., Heideman, R. L., Meyer, W. H., Gajjar, A. J., Crom, W. R., and Stewart, C. F. Pharmacokinetics (PK) of topotecan in pediatric patients with normal and altered renal function. Proc. Am. Soc. Clin. Oncol., 15: 371, 1996.
11. O'Reilly, S., Rowinsky, E., Slichenmyer, W., Donehower, R. C., Forastiere, A., Ettinger, D., Chen, T-L., Sartorius, S., Bowling, K., Smith, J., Brubaker, A., Lubejko, B., Ignacio, V., and Grochow, L. Phase I and pharmacologic studies of topotecan in patients with impaired hepatic function. J. Natl. Cancer Inst., 88: 817-824, 1996.
12. Rosing, H., Herben, V. M. M., van Gortel-van Zomeren, D. M., Hop, E., Kettenes-van den Bosch, J., ten Bokkel Huinink, W. W., and Beijnen, J. H. Isolation and structural confirmation of N-desmethyl topotecan, a metabolite of topotecan. Cancer Chemother. Pharmacol., 39: 498-504, 1997.
13. Stewart, C. F., Baker, S. D., Crom, W. R., and Pratt, C. B. Clinical pharmacokinetics of topotecan (T) in children with cancer. Proc. Am. Assoc. Cancer Res., 34: 395, 1993.
14. Hormans, Y., Kanyinda, J., and Desager, J. Relationship between mephenytoin, phenytoin and tolbutamide hydroxylations in healthy African subjects. Pharmacol. Toxicol., 78: 86-88, 1996.
15. Ibeanu, G., and Goldstein, J. Transcriptional regulation of human CYP2C genes: functional comparisons of CYP2C9 and CYP2C18 promoter regions. Biochemistry, 54: 8028-8026, 1995.
16. Hashimoto, Y., Otsuki, Y., Odani, A., Takano, M., Hattori, H., Furusho, K., and Iui, K. Effect of CYP2C polymorphisms on the pharmacokinetics of phenytoin in Japanese patients with epilepsy. Biol. Pharmaceut. Bull., 19: 1103-1105, 1996.
17. Ghosal, A., Sadrieh, N., Reik, L., Levin, W., and Thomas, P. Induction of the male-specific cytochrome P450 3A2 in female rats by phenytoin. Arch. Biochem. Biophys., 332: 153-162, 1996.
18. Fleishaker, J., Pearson, L., and Peters, G. Phenytoin causes a rapid increase in 6β-hydroxycortisol urinary excretion in humans-a putative measure of CYP3A induction. J. Pharmaceut. Sci., 84: 292-294, 1995.
19. Nims, R., McClain, R., Manchand, P., Belica, P., Thomas, P., Mellini, D., Utermahlen, W., and Lubet, R. Comparative pharmacodynamics of hepatic cytochrome P450 2B induction by 5,5-diphenyl-and 5,5-diethyl-substituted barbiturates and hydantoins in the male F344/ NCr rat. J. Pharmacol. Exp. Ther., 270: 348-355, 1994.
20. Liu, H., and Delgado, M. Interactions of phenobarbital and phenytoin with carbamazepine and its metabolites concentrations, concentration ratios, and level/dose ratios in epileptic children. Epilepsia, 36: 249-254, 1995.
21. Stewart, C. F., Gajjar, A. J., Heideman, R. L., Houghton, P. J., and Zamboni, W. C. Phenytoin increases topotecan (TPT) clearance in a patient with medulloblastoma (MB). Proc. Am. Soc. Clin. Oncol., 16: 251, 1997.
22. Houghton, P. J., Cheshire, P. J., Hallman, J. D., Lutz, L., Friedman, H. S., Danks, M. K., and Houghton, J. A. Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors. Cancer Chemother. Pharmacol., 36: 393-403, 1995.
23. Friedman, H. S., Houghton, P. J., Schold, S. C., Keir, S., and Bigner, D. D. Activity of 9-dimethylaminomethyl-10-hydroxycamptothecin against pediatric and adult central nervous system tumor xenografts. Cancer Chemother. Pharmacol., 34: 171-174, 1994.
24. Blaney, S. M., Cole, D. E., Balis, F. M., Godwin, K., and Poplack, D. G. Plasma and cerebrospinal fluid pharmacokinetic study of topotecan in nonhuman primates. Cancer Res., 53: 725-727, 1993.
25. Baker, S. D., Heideman, R. L., Crom, W. R., Kuttesch, J. F., Gajjar, A., and Stewart, C. F. Cerebrospinal pharmacokinetics and penetration of continuous infusion topotecan in children with central nervous system tumors. Cancer Chemother. Pharmacol., 37: 195-202, 1996.
26. Beijnen, J. H., Smith, B. R., Keijer, W. J., Van Gijn, R., Huinink, W. W., Vlasveld, L. T., Rodenhuis, S., and Underberg, W. J. M. High-performance liquid Chromatographie analysis of the new antitumour drug SK&F 104864-A (NSC 609699) in plasma. J. Pharm. Biomed. Anal., 8: 789-794, 1990.
27. Rosing, H., Doyle, E., Davies, B. E., and Beijnen, J. High-performance liquid Chromatographie determination of the novel antitumor drug topotecan and topotecan as the total of the lactone plus carboxylate forms, in human plasma. J. Chromatogr. Biol. Biomed. Appl., 668: 107-115, 1997.
28. D'Argenio, D. Z., and Schumitzky, A. ADAPT II Users Guide, University of Southern California. Los Angeles: Biomedical Simulations Resource, 1990.
29. D'Argenio, D. Z., and Schumitzky, A. A program package for simulation and parameter estimation in pharmacokinetic systems. Comput. Prog. Biomed., 9: 115-134, 1979.
30. Tubergen, D. G., Stewart, C. F., Pratt, C. B., Zamboni, W. C., Winick, N., Santana, V. M., Dryer, Z. A., Kurtzberg, J., Bell, B., Grier, H., and Vietti, T. J. Phase I trial and pharmacokinetic (PK) and pharmacodynamics (PD) study of topotecan using a five-day course in children with refractory solid tumors: a Pediatric Oncology Group Study. J. Pediatr. Hematol./Oncol., 18: 352-361, 1996.
31. Gibaldi, M., and Perrier, D. Pharmacokinetics. New York: Marcel Dekker, 1982.
32. Sugimoto, Y., Muro, H., Woo, M., Nishida, N., and Murakami, K. Valproate metabolites in high-dose valproate plus phenytoin therapy. Epilepsia, 37: 1200-1203, 1996.
33. Tozer, T., and Winter, M. Phenytoin. In: W. E. Evans, J. J. Schentag, and W. J. Jusko (eds.), Applied Pharmacokinetics: Principles of Therapeutic Drug Monitoring, pp. 25-1-25-44. Vancover, WA: Applied Therapeutics, 1992.
34. Rodman, J. H., Murry, D. J., Madden, T., and Santana, V. M. Altered etoposide pharmacokinetics and time to engraftment in pediatric patients undergoing autologous bone marrow transplantation. J. Clin. Oncol., 12: 2390-2397, 1994.
35. Baker, D. K., Relling, M. V., Pui, C-H., Christensen, M. L., Evans, W. E., and Rodman, J. H. Increased teniposide clearance with concomitant anticonvulsant therapy. J. Clin. Oncol., 10: 311-315, 1992.
36. Fetell, M. R., Grossman, S. A., Fish, J. D., Erlanger, B., Rowinsky, E. S. J., and Piantadosi, S. Preirradiation paclitaxel in glioblastoma multiforme: efficacy, pharmacology, and drug interactions. J. Clin. Oncol., 15: 3121-3128, 1997.
37. Grossman, S. A., Hochberg, F., Fisher, J., Chen, T. L., Kim, L., Gregory, R., and Grochow, L. B. Increased 9-aminocamptothecin (9-AC) dose requirements in patients on anticonvulsants (AC). Proc. Am. Soc. Clin. Oncol., 16: 389, 1997.
38. Sonnichsen, D. S., Liu, Q., Schuetz, E. G., Schuetz, J. D., Pappo, A. S., and Relling, M. V. Variability in human cytochrome P450 paclitaxel metabolism. J. Pharmacol. Exp. Ther., 275: 566-575, 1995.